Skip to Content

No Increased Risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

Dr. Jeff Sharman presents compelling data from multiple clinical trials, revealing the safety of acalabrutinib in treating blood disorders. The research, encompassing around 4,000 patient-years of acalabrutinib treatment, demonstrates no significant association with ventricular arrhythmias, a concern in similar therapies.

Jeff P. Sharman

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top